IT1246382B - Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon - Google Patents

Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon

Info

Publication number
IT1246382B
IT1246382B IT02005490A IT2005490A IT1246382B IT 1246382 B IT1246382 B IT 1246382B IT 02005490 A IT02005490 A IT 02005490A IT 2005490 A IT2005490 A IT 2005490A IT 1246382 B IT1246382 B IT 1246382B
Authority
IT
Italy
Prior art keywords
colon
intestine
active principle
targeted
permeable
Prior art date
Application number
IT02005490A
Other languages
English (en)
Other versions
IT9020054A0 (it
IT9020054A1 (it
Inventor
Massimo Maria Calanchi
Marco Zema
Enzo Giorgetti
Gabriele Brunetti
Original Assignee
Eurand Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Int filed Critical Eurand Int
Publication of IT9020054A0 publication Critical patent/IT9020054A0/it
Priority to IT02005490A priority Critical patent/IT1246382B/it
Priority to CA002035155A priority patent/CA2035155A1/en
Priority to EP91200173A priority patent/EP0453001A1/en
Priority to JP02778491A priority patent/JP3194974B2/ja
Priority to DE69122751T priority patent/DE69122751T2/de
Priority to KR1019920702558A priority patent/KR100196256B1/ko
Priority to JP91506876A priority patent/JPH05506217A/ja
Priority to SG1996006208A priority patent/SG46584A1/en
Priority to EP91907396A priority patent/EP0524989B1/en
Priority to AU76798/91A priority patent/AU654277B2/en
Priority to PCT/EP1991/000688 priority patent/WO1991016042A1/en
Priority to RU92016377A priority patent/RU2111743C1/ru
Priority to DK91907396.5T priority patent/DK0524989T3/da
Priority to ES91907396T priority patent/ES2093097T3/es
Priority to AT91907396T priority patent/ATE144138T1/de
Priority to NZ237823A priority patent/NZ237823A/en
Priority to PT97370A priority patent/PT97370B/pt
Priority to CA002040471A priority patent/CA2040471A1/en
Priority to ZA912792A priority patent/ZA912792B/xx
Priority to IE127191A priority patent/IE911271A1/en
Priority to TW080102920A priority patent/TW223022B/zh
Publication of IT9020054A1 publication Critical patent/IT9020054A1/it
Priority to US07/972,660 priority patent/US5900252A/en
Application granted granted Critical
Publication of IT1246382B publication Critical patent/IT1246382B/it
Priority to GR960403247T priority patent/GR3021847T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IT02005490A 1990-04-17 1990-04-17 Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon IT1246382B (it)

Priority Applications (23)

Application Number Priority Date Filing Date Title
IT02005490A IT1246382B (it) 1990-04-17 1990-04-17 Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
CA002035155A CA2035155A1 (en) 1990-04-17 1991-01-29 Pharmaceutical composition for the targeted controlled release of an active principle within the intestine, and particularly within the colon
EP91200173A EP0453001A1 (en) 1990-04-17 1991-01-29 Pharmaceutical composition for the targeted controlled release of an active principle within the intestine, and particularly within the colon
JP02778491A JP3194974B2 (ja) 1990-04-17 1991-01-30 標的制御釈放薬剤
DK91907396.5T DK0524989T3 (da) 1990-04-17 1991-04-09 Medikamentpræparat med reguleret frigivelse
KR1019920702558A KR100196256B1 (ko) 1990-04-17 1991-04-09 서방성 약물 제형
JP91506876A JPH05506217A (ja) 1990-04-17 1991-04-09 制御放出薬剤処方
SG1996006208A SG46584A1 (en) 1990-04-17 1991-04-09 Controlled release drug formulation
EP91907396A EP0524989B1 (en) 1990-04-17 1991-04-09 Controlled release drug formulation
AU76798/91A AU654277B2 (en) 1990-04-17 1991-04-09 Controlled release drug formulation
PCT/EP1991/000688 WO1991016042A1 (en) 1990-04-17 1991-04-09 Controlled release drug formulation
RU92016377A RU2111743C1 (ru) 1990-04-17 1991-04-09 Многокомпонентная дозированная форма с контролируемым выделением активного ингредиента
DE69122751T DE69122751T2 (de) 1990-04-17 1991-04-09 Arzneimittelzusammensetzung mit kontrollierter wirkstoffabgabe
ES91907396T ES2093097T3 (es) 1990-04-17 1991-04-09 Formulacion de farmacos de cesion controlada.
AT91907396T ATE144138T1 (de) 1990-04-17 1991-04-09 Arzneimittelzusammensetzung mit kontrollierter wirkstoffabgabe
NZ237823A NZ237823A (en) 1990-04-17 1991-04-15 Formulation of particles comprising an active ingredient core surrounded by two polymer membranes, one soluble at ph over 5 and one insoluble but permeable to gastrointestinal fluid
PT97370A PT97370B (pt) 1990-04-17 1991-04-15 Processo para a preparacao de uma formulacao de libertacao controlada sob a forma de uma pluralidade de unidades multidose
CA002040471A CA2040471A1 (en) 1990-04-17 1991-04-15 Controlled release drug formulation
ZA912792A ZA912792B (en) 1990-04-17 1991-04-15 Controlled release drug formulation
IE127191A IE911271A1 (en) 1990-04-17 1991-04-16 Controlled release drug formulation
TW080102920A TW223022B (it) 1990-04-17 1991-04-16
US07/972,660 US5900252A (en) 1990-04-17 1992-11-06 Method for targeted and controlled release of drugs in the intestinal tract and more particularly in the colon
GR960403247T GR3021847T3 (en) 1990-04-17 1996-11-29 Controlled release drug formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT02005490A IT1246382B (it) 1990-04-17 1990-04-17 Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon

Publications (3)

Publication Number Publication Date
IT9020054A0 IT9020054A0 (it) 1990-04-17
IT9020054A1 IT9020054A1 (it) 1991-10-17
IT1246382B true IT1246382B (it) 1994-11-18

Family

ID=11163447

Family Applications (1)

Application Number Title Priority Date Filing Date
IT02005490A IT1246382B (it) 1990-04-17 1990-04-17 Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon

Country Status (20)

Country Link
US (1) US5900252A (it)
EP (2) EP0453001A1 (it)
JP (2) JP3194974B2 (it)
KR (1) KR100196256B1 (it)
AT (1) ATE144138T1 (it)
AU (1) AU654277B2 (it)
CA (2) CA2035155A1 (it)
DE (1) DE69122751T2 (it)
DK (1) DK0524989T3 (it)
ES (1) ES2093097T3 (it)
GR (1) GR3021847T3 (it)
IE (1) IE911271A1 (it)
IT (1) IT1246382B (it)
NZ (1) NZ237823A (it)
PT (1) PT97370B (it)
RU (1) RU2111743C1 (it)
SG (1) SG46584A1 (it)
TW (1) TW223022B (it)
WO (1) WO1991016042A1 (it)
ZA (1) ZA912792B (it)

Families Citing this family (419)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
IT1260505B (it) * 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
WO1995016451A1 (fr) * 1992-06-22 1995-06-22 Franck Arno Gouchet Comprimes a liberation controlee de 4-asa
FR2692484B1 (fr) * 1992-06-22 1995-06-30 Gouchet Franck Nouvelle forme galenique de 4-asa a liberation controlee.
ATE217188T1 (de) * 1992-08-05 2002-05-15 Faulding F H & Co Ltd Granulierte pharmazeutische zusammensetzung
AU670958B2 (en) * 1992-08-05 1996-08-08 Mayne Pharma International Pty Ltd Pelletised pharmaceutical composition
US5358502A (en) 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1265092B1 (it) * 1993-05-31 1996-10-30 Giuliani Spa Preparato per uso come integratore alimentare, o dietetico,a rilascio mirato nel colon
DE4332394A1 (de) * 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5536505A (en) * 1993-12-15 1996-07-16 Eastman Chemical Company Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
US5523095A (en) * 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
ATE357221T1 (de) 1994-04-22 2007-04-15 Astellas Pharma Inc Kolon-spezifisches arzneistofffreisetzungssystem
AT403988B (de) * 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
CA2240281C (en) * 1995-12-21 2007-02-27 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
AUPO247496A0 (en) 1996-09-23 1996-10-17 Resmed Limited Assisted ventilation to match patient respiratory need
WO1998026767A2 (en) * 1996-12-17 1998-06-25 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
AU5310898A (en) * 1996-12-20 1998-07-17 Dumex-Alpharma A/S Release-controlled coated tablets
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
DK1017392T3 (da) * 1997-09-25 2002-10-21 Bayer Ag Lægemiddel
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
DE59905248D1 (de) 1999-01-29 2003-05-28 Disphar Int Bv Pharmazeutische zusammensetzungen
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
WO2000076478A1 (en) 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
US7166719B2 (en) 2002-06-27 2007-01-23 Health Research, Inc. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
US7897140B2 (en) * 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US6451345B1 (en) 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
IT1318625B1 (it) 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
KR100790056B1 (ko) 2000-09-06 2007-12-31 미쯔비시 웰 파마 가부시키가이샤 경구용 입제제(粒製劑)
RU2191782C2 (ru) * 2000-09-21 2002-10-27 Институт нефтехимии и катализа АН РБ и УНЦ РАН Способ получения модифицированной гиалуроновой кислоты
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
TR200300731T2 (tr) 2000-11-28 2004-08-23 Fmc Corporation Yenebilir PGA kaplama bileşimi
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
WO2002072033A2 (en) 2001-03-13 2002-09-19 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms containing glucocorticosteroid
US20040156900A1 (en) * 2001-04-10 2004-08-12 Shanghvi Dilip Shantilal Time pulsed release composition
KR20010069756A (ko) * 2001-05-08 2001-07-25 유형선 소염진통제인 아세메타신을 함유하며 장관내 특히대장에서의 약물 방출 속도가 조절되는 약물 전달 체계에대한 약제학적 경구용 조성물 및 그에 대한 제조방법
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
AR036797A1 (es) 2001-10-15 2004-10-06 Ferring Bv Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
EP1446110A2 (en) * 2001-10-16 2004-08-18 Structural Bioinformatics Inc. Organosulfur inhibitors of tyrosine phosphatases
PT1453487E (pt) * 2001-11-23 2008-05-13 Procter & Gamble Forma de dosagem farmacêutica com revestimentos múltiplos
US20030133982A1 (en) * 2001-12-20 2003-07-17 Heimlich John M. Zero-order sustained release dosage forms and method of making same
RU2220716C1 (ru) * 2002-04-24 2004-01-10 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М.Сеченова Способ получения микрокапсул, содержащих живые микроорганизмы
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US7053210B2 (en) * 2002-07-02 2006-05-30 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
ES2621203T3 (es) * 2002-08-14 2017-07-03 Givaudan S.A. Composiciones que comprenden un material encapsulado
EP1393706A1 (en) * 2002-08-14 2004-03-03 Quest International B.V. Fragranced compositions comprising encapsulated material
WO2004041244A2 (en) * 2002-10-30 2004-05-21 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
BRPI0408805A (pt) * 2003-03-31 2006-03-28 Pliva Lachema As composição farmacêutica contendo complexo de platina e método de fabricação da mesma
WO2004093883A2 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US20040242886A1 (en) * 2003-04-30 2004-12-02 Sandeep Gupta Monocyclic diazodioxide based Bcl-2 protein antagonists related applications
US20040248877A1 (en) * 2003-04-30 2004-12-09 Sandeep Gupta Polycyclic diazodioxide-based Bcl-2 protein antagonists and use thereof
EP1628666B1 (en) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US20090227647A1 (en) * 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
AP2006003585A0 (en) 2003-09-19 2006-04-30 Penwest Pharmaceuticals Co Delayed release dosage forms.
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
DE602004030931D1 (it) 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
EP1547601A1 (en) 2003-12-23 2005-06-29 Ferring B.V. Coating method
AU2004311879B2 (en) * 2003-12-31 2010-08-05 Phoenix Labs Unlimited Company Effervescent oral opiate dosage form
US7858121B2 (en) * 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
CA2548915C (en) * 2003-12-31 2012-10-16 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
AU2005245470A1 (en) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US20060135773A1 (en) * 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
WO2006017124A2 (en) * 2004-07-09 2006-02-16 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1841749A1 (en) 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
NZ554545A (en) 2004-09-17 2010-10-29 Whitehead Inst Of Biomedical R Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
US20060067889A1 (en) * 2004-09-27 2006-03-30 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
WO2006130217A2 (en) * 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
WO2007002109A2 (en) * 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007076160A2 (en) * 2005-12-28 2007-07-05 Acidophil Llc C-10 carbamates of taxanes
KR101419554B1 (ko) * 2006-03-13 2014-07-17 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ­３ 억제제로서 아미노퀴놀론
JP2009531443A (ja) * 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EA015304B1 (ru) 2006-08-03 2011-06-30 Нитек Фарма Аг Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
EP2068844A4 (en) * 2006-09-04 2013-01-23 Panacea Biotec Ltd PROGRAMMABLE RELEASE TECHNIQUE BY FLOATING SYSTEM
PT2066662E (pt) 2006-09-21 2013-02-13 Kyorin Seiyaku Kk Inibidores de serina-hidrolase
CA2666149A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US20100137421A1 (en) * 2006-11-08 2010-06-03 Emmanuel Theodorakis Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
CA2673566A1 (en) 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
KR20090086115A (ko) * 2006-12-22 2009-08-10 엔싸이시브 파마슈티칼즈 인코퍼레이티드 Ｃ３ａ 수용체의 조정제 및 이의 사용 방법
HRP20110713T1 (hr) * 2007-02-28 2011-11-30 Conatus Pharmaceuticals Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
AU2008251773A1 (en) 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
US8911749B2 (en) 2007-04-16 2014-12-16 Corium International, Inc. Vaccine delivery via microneedle arrays
CA2686093C (en) 2007-04-16 2018-05-08 Corium International, Inc. Solvent-cast microneedle arrays containing active
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
PT2152250T (pt) 2007-05-07 2019-12-12 Evonik Operations Gmbh Formas farmacêuticas sólidas que compreendem um revestimento entérico com libertação acelerada do fármaco
AU2008274941A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
BRPI0816798A2 (pt) * 2007-09-11 2016-10-11 Activx Biosciences Inc composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
CN101855229A (zh) 2007-09-12 2010-10-06 埃迪威克斯生物科学公司 作为gsk-3抑制剂的螺环状氨基喹诺酮
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
KR20100116165A (ko) * 2007-10-12 2010-10-29 다케다 파마슈티칼스 노쓰 어메리카, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
JP2011504485A (ja) * 2007-11-21 2011-02-10 ファーマクシス リミテッド Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途
HUE025197T2 (en) 2008-03-17 2016-02-29 Ambit Biosciences Corp Quinazoline derivatives as RAF kinase modulators and methods for their use
US20120034156A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
CN101658533A (zh) * 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送
EP2334178A4 (en) 2008-10-03 2012-04-11 Falk Pharma Gmbh COMPOSITIONS AND METHODS OF TREATING THERAPEUTIC DISEASES WITH GRANULATED MESALAMINE
SI3121280T1 (sl) 2008-11-13 2025-08-29 Nogra Pharma Limited Antismiselne sestave in postopki za njihovo izdelavo ter uporabo
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
PL2401267T3 (pl) 2009-02-27 2014-06-30 Ambit Biosciences Corp Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
BRPI1008974A2 (pt) * 2009-03-11 2017-06-06 Kyorin Seiyaku Kk composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
US8461158B2 (en) 2009-03-27 2013-06-11 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010123959A2 (en) 2009-04-22 2010-10-28 Axikin Pharmaceuticals, Inc. 2,5-disubstituted arylsulfonamide ccr3 antagonists
PL2421829T3 (pl) 2009-04-22 2016-03-31 Axikin Pharmaceuticals Inc 2,5-dipodstawione arylosulfonamidy jako antagoniści CCR3
HUE025647T2 (en) 2009-04-22 2016-04-28 Axikin Pharmaceuticals Inc Arylsulfonamide CCR3 antagonists
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
ES2655883T5 (es) 2009-07-08 2022-04-18 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Composiciones farmacéuticas que contienen tiosulfato de sodio
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
BR112012003661A2 (pt) 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
RU2419422C1 (ru) * 2009-11-05 2011-05-27 Федеральное государственное учреждение науки Центральный научно-исследовательский институт эпидемиологии Роспотребнадзора РФ Способ коррекции функциональных нарушений билиарного тракта у детей, больных острыми кишечными инфекциями
WO2011057214A2 (en) 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
AR079528A1 (es) 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
US8710092B2 (en) * 2009-12-23 2014-04-29 Map Pharmaceuticals, Inc. Substituted indolo 4,3 FG quinolines useful for treating migraine
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
RU2012140421A (ru) 2010-02-23 2014-03-27 Да Волтерра Лекарственные формы для пероральной доставки адсорбентов в кишечник
US8999995B2 (en) 2010-03-02 2015-04-07 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
US8741894B2 (en) 2010-03-17 2014-06-03 Axikin Pharmaceuticals, Inc. Arylsulfonamide CCR3 antagonists
ES2719595T3 (es) 2010-05-04 2019-07-11 Corium Int Inc Método y dispositivo para la administración transdérmica de la hormona paratiroidea usando una matriz de microproyección
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
CN103153309A (zh) 2010-06-01 2013-06-12 拜欧赛里克斯公司 使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法
CN104945318A (zh) 2010-06-01 2015-09-30 拜欧赛里克斯公司 羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
SG186229A1 (en) 2010-06-07 2013-01-30 Novomedix Llc Furanyl compounds and the use thereof
CA2805745C (en) 2010-07-19 2019-01-15 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
CN103298805A (zh) 2010-09-01 2013-09-11 埃姆比特生物科学公司 喹唑啉化合物及其使用方法
EP2611793A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
WO2012030914A1 (en) 2010-09-01 2012-03-08 Ambit Boisciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
US8633209B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
US20120053176A1 (en) 2010-09-01 2012-03-01 Ambit Biosciences Corp. Adenosine a3 receptor modulating compounds and methods of use thereof
WO2012030913A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
WO2012030924A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
EP2627635A1 (en) 2010-10-11 2013-08-21 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
CA2825152A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
BR112013024909A2 (pt) 2011-03-28 2019-09-24 Mei Pharma Inc composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
EP2691388A1 (en) 2011-03-28 2014-02-05 MEI Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
CA2831582C (en) 2011-03-28 2019-01-08 Mei Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
JP5813391B2 (ja) * 2011-06-24 2015-11-17 日東電工株式会社 粒子製剤の製造方法
JP2014517076A (ja) 2011-06-23 2014-07-17 マップ・ファーマシューティカルズ・インコーポレイテッド 新規のフルオロエルゴリン類似体
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
CA2851155C (en) 2011-10-14 2021-02-23 Ambit Biosciences Corporation Heterocyclic compounds and methods of use thereof
EP2599477A1 (en) 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
SG10201509139QA (en) 2011-12-19 2015-12-30 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
SG10201506202RA (en) 2011-12-21 2015-09-29 Map Pharmaceuticals Inc Novel neuromodulatory compounds
JP2012107058A (ja) * 2012-02-27 2012-06-07 Warner Chilcott Co Llc 複数のコーティングを有する医薬剤形
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
AU2013229990B2 (en) * 2012-03-07 2017-07-06 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
AU2013205306B2 (en) 2012-03-16 2015-09-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
JP6203816B2 (ja) 2012-03-29 2017-09-27 セラバイオーム，エルエルシー 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤
PT2844637T (pt) 2012-05-02 2018-04-17 Boehringer Ingelheim Int Inibidores de 3-haloalilamina substituídos de ssao e as suas utilizações
CN103417380B (zh) * 2012-05-22 2016-01-06 正和制药股份有限公司 具有肠溶膜衣的硬胶囊
US9732038B2 (en) 2012-06-14 2017-08-15 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of STAT3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
RU2681730C2 (ru) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
WO2014033077A1 (en) 2012-08-28 2014-03-06 Dsm Sinochem Pharmaceuticals Netherlands B.V. Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets
KR20150053906A (ko) 2012-09-07 2015-05-19 액시킨 파마수티컬스 인코포레이티드 동위원소 농축 아릴설폰아미드 ccr3 길항제
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
WO2014074765A2 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
CN107698470A (zh) 2012-11-30 2018-02-16 诺沃梅迪科斯有限公司 取代的二芳基磺酰胺及其用途
BR112015014969B1 (pt) 2012-12-21 2021-12-07 Corium, Inc Aparelho de microestruturas e método de fabricar um aparelho de microestruturas
CA2895829A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel methysergide derivatives
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
AU2014205324A1 (en) 2013-01-11 2015-07-30 Mayo Foundation For Medical Education And Research Vitamins C and K for treating polycystic diseases
JP6487899B2 (ja) 2013-03-12 2019-03-20 コリウム インターナショナル， インコーポレイテッド 微小突起アプリケータ
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
ES2921174T3 (es) 2013-03-15 2022-08-19 Corium Inc Conjunto de microestructuras para el suministro de agentes activos, método de fabricación del conjunto de microestructuras y formulación líquida del mismo
BR112015022625B1 (pt) 2013-03-15 2023-01-31 Corium, Inc Aparelho de microestrutura para entrega de agente terapêutico
WO2014144973A1 (en) 2013-03-15 2014-09-18 Corium International, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
JP2016514133A (ja) 2013-03-15 2016-05-19 コリウム インターナショナル， インコーポレイテッド ポリマーを含まない微細構造物を含むマイクロアレイ、製造方法および使用方法
AU2014237357B2 (en) 2013-03-15 2019-11-28 Corium Pharma Solutions, Inc. Multiple impact microprojection applicators and methods of use
US9763887B2 (en) 2013-03-15 2017-09-19 Allergan Pharmaceuticals International Limited Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
EP3039021A1 (en) 2013-08-30 2016-07-06 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015127351A1 (en) 2014-02-24 2015-08-27 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
KR102409739B1 (ko) 2014-03-20 2022-06-17 카펠라 테라퓨틱스, 인크. 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
EP3119762B9 (en) 2014-03-20 2021-10-20 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
MX2016014731A (es) 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
AU2015266958A1 (en) 2014-05-28 2016-12-08 Agenus Inc. Anti-GITR antibodies and methods of use thereof
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
AU2015308618B2 (en) 2014-08-29 2021-05-20 Corium Pharma Solutions, Inc. Microstructure array for delivery of active agents
EP3188714A1 (en) 2014-09-04 2017-07-12 Corium International, Inc. Microstructure array, methods of making, and methods of use
CN106999593A (zh) 2014-09-12 2017-08-01 妥必徕疗治公司 用于纤维化治疗的赛尼克韦罗组合疗法
WO2016065264A1 (en) 2014-10-24 2016-04-28 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
CA2970352A1 (en) 2014-12-11 2016-06-16 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
US10221248B2 (en) 2014-12-22 2019-03-05 The Rockefeller University Anti-MERTK agonistic antibodies and uses thereof
CN107250116B (zh) 2014-12-23 2020-10-27 艾士盟医疗公司 3,5-二氨基吡唑激酶抑制剂
JP2018502889A (ja) 2015-01-20 2018-02-01 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ イソエルゴリン化合物およびその使用
WO2016118541A1 (en) 2015-01-20 2016-07-28 Xoc Pharmaceuticals, Inc Ergoline compounds and uses thereof
HK1247203A1 (zh) 2015-01-28 2018-09-21 上海复旦张江生物医药股份有限公司 取代的咪唑并[1，2-α]吡啶-2-基胺化合物及其药物组合物和使用方法
HRP20230046T1 (hr) 2015-03-03 2023-03-03 Kymab Limited Protutijela, upotreba i postupci
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
MX390795B (es) 2015-06-23 2025-03-21 Neurocrine Biosciences Inc Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos.
WO2017004067A1 (en) 2015-06-29 2017-01-05 Corium International, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
CN115304596A (zh) 2015-10-30 2022-11-08 纽罗克里生物科学有限公司 Valbenazine盐及其多晶形物
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CA3006966A1 (en) 2015-12-02 2017-06-08 Astraea Therapeutics, Llc Piperidinyl nociceptin receptor compounds
SI3394057T1 (sl) 2015-12-23 2022-06-30 Neurocrine Biosciences, Inc. Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
CN108697663A (zh) 2015-12-31 2018-10-23 科内图斯医药公司 在肝病治疗中使用胱天蛋白酶抑制剂的方法
WO2017120415A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
BR112018013761A2 (pt) 2016-01-08 2018-12-11 Celgene Corp compostos antiproliferativos e suas composições farmacêuticas e usos
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
WO2017156191A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
JP2019513151A (ja) 2016-03-08 2019-05-23 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． カンプトテシン誘導体及びその使用
EP3429573A4 (en) 2016-03-17 2019-10-30 Thiogenesis Therapeutics, Inc. COMPOSITIONS FOR THE CONTROLLED RELEASE OF CYSTEAMINE AND FOR SYSTEMIC TREATMENT OF CYSTEAMIN SENSITIVE DISEASES
EP3442940A1 (en) 2016-04-11 2019-02-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
CA3021066C (en) * 2016-04-19 2024-04-09 Ferring B.V. Oral pharmaceutical compositions of nicotinamide
RU2744576C2 (ru) * 2016-04-19 2021-03-11 Ферринг Б.В. Пероральные фармацевтические композиции месалазина
DK3454904T3 (da) 2016-05-13 2023-02-06 Pasteur Institut Inhibering af beta-2-nikotiniske acetylcholinreceptorer til at behandle patologi ved Alzheimers sygdom
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
JP2019529419A (ja) 2016-09-19 2019-10-17 エムイーアイ ファーマ，インク． 併用療法
TW202436356A (zh) 2016-10-11 2024-09-16 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR102539159B1 (ko) 2016-11-07 2023-06-02 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
CN117069622A (zh) 2016-11-09 2023-11-17 诺沃梅迪科斯有限公司 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
US10836774B2 (en) 2016-11-30 2020-11-17 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
JP7105774B2 (ja) 2016-12-01 2022-07-25 イグナイタ インコーポレイテッド がん治療のための方法
WO2018102673A1 (en) 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
US11013802B2 (en) 2016-12-07 2021-05-25 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
MY199695A (en) 2017-01-27 2023-11-18 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
CN116730921A (zh) 2017-02-17 2023-09-12 文涵治疗有限公司 Ag-10的制备方法、其中间体及其盐
AU2018220515B2 (en) 2017-02-17 2022-06-30 DayLife LLC Universal antivenom
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
MX2019011624A (es) 2017-03-27 2019-12-05 Celgene Corp Metodos y composiciones para la reduccion de la inmunogenicidad.
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
US12042566B2 (en) 2017-05-17 2024-07-23 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof
MX2019014272A (es) 2017-06-01 2020-12-11 Xoc Pharmaceuticals Inc Compuestos policiclicos y usos de los mismos.
KR102905526B1 (ko) 2017-06-27 2025-12-30 주식회사 뉴라클사이언스 항-fam19a5 항체 및 이의 용도
KR20220031738A (ko) 2017-06-27 2022-03-11 주식회사 뉴라클사이언스 암 치료를 위한 항-fam19a5 항체의 용도
EP3645039A4 (en) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
EP3645044A4 (en) 2017-06-27 2021-04-28 Neuracle Science Co., Ltd USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, ELEMENT A5 ANTIBODIES TO TREAT GLAUCOMA
ES2953032T3 (es) 2017-09-01 2023-11-07 Univ East Carolina Métodos ex vivo para la activación de las células inmunológicas
ES2938609T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión
CN111683684B (zh) 2017-09-20 2024-07-02 硫创治疗公司 用于治疗半胱胺敏感性病症的方法
DK3684333T3 (da) 2017-09-21 2025-05-12 Neurocrine Biosciences Inc Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil
WO2019069229A1 (en) 2017-10-02 2019-04-11 Neuracle Science Co., Ltd. USE OF ANTIBODIES DIRECTED AGAINST A SIMILARITY FAMILY OF SEQUENCE 19, ELEMENT A5, FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS
MX2020004133A (es) 2017-10-04 2020-08-13 Univ California Oligosacaridos inmunomoduladores.
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
SG11202003980PA (en) 2017-10-31 2020-05-28 Staten Biotechnology B V Anti-apoc3 antibodies and methods of use thereof
EP3501503A1 (en) 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
US20210052529A1 (en) 2018-01-10 2021-02-25 Cura Therapeutics, Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
WO2019139869A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
MA52137A (fr) 2018-03-23 2021-01-27 Eidos Therapeutics Inc Méthodes de traitement de l'amylose ttr à l'aide d'ag10
KR20200118913A (ko) 2018-04-24 2020-10-16 주식회사 뉴라클사이언스 신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
CN112074605B (zh) 2018-05-08 2024-11-22 纽洛可科学有限公司 抗fam19a5抗体的腺相关病毒（aav）递送
CA3098805A1 (en) 2018-05-10 2019-11-14 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
CA3105352A1 (en) 2018-06-29 2020-01-02 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
MA53160A (fr) 2018-07-20 2021-05-26 Pf Medicament Récepteur pour vista
BR112021000019A2 (pt) 2018-08-15 2021-04-06 Neurocrine Biosciences Inc. Métodos para administração de certos inibidores de vmat2
JP7469293B2 (ja) 2018-08-17 2024-04-16 エイドス セラピューティクス，インコーポレイティド Ａｇ１０の製剤
EP3860713A2 (en) 2018-10-03 2021-08-11 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
EP3867272A4 (en) 2018-10-16 2022-08-03 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES
US20220008515A1 (en) 2018-11-16 2022-01-13 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
WO2020118042A1 (en) 2018-12-05 2020-06-11 Jacobs Wagner Christine Borrelia burgdorferi peptidoglycan as a diagnostic and target for therapeutic intervention of lyme disease-related pathologies
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
IT201800011120A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
KR102757347B1 (ko) 2018-12-27 2025-01-23 주식회사 뉴라클사이언스 죽상경화증을 치료하기 위한 항-fam19a5 항체의 사용
CN117964756A (zh) 2019-01-02 2024-05-03 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体及其使用方法
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
CN113874081A (zh) 2019-02-26 2021-12-31 茵思博纳公司 高-亲和力抗-mertk抗体及其用途
JP7645192B2 (ja) 2019-03-07 2025-03-13 ノボ メディシン インク． カスパーゼ阻害剤及びその使用方法
ES3036313T3 (en) 2019-05-20 2025-09-17 Nirvana Sciences Inc Narrow emission dyes, compositions comprising same, and methods for making and using same
WO2020236818A1 (en) 2019-05-20 2020-11-26 Nirvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
EP3996813A1 (en) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
CA3146157A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
MX2022001865A (es) 2019-08-12 2022-03-11 Massachusetts Inst Technology Articulos y metodos para la administracion de agentes terapeuticos.
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
AU2020335928A1 (en) 2019-08-30 2022-02-17 Agenus Inc. Anti-CD96 antibodies and methods of use thereof
JP7566889B2 (ja) 2019-09-16 2024-10-15 ダイス・アルファ・インコーポレイテッド Ｉｌ－１７ａモジュレーターおよびその使用
JP2023512456A (ja) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
EP4093751A1 (en) 2020-01-22 2022-11-30 Outpace Bio, Inc. Chimeric polypeptides
WO2021158783A1 (en) 2020-02-05 2021-08-12 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
CA3179635A1 (en) 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
EP4168414A1 (en) 2020-06-18 2023-04-26 Shy Therapeutics LLC Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP4149471A4 (en) 2020-06-30 2024-07-10 Prosetta Biosciences, Inc. ISOQUINOLINE DERIVATIVES, PROCESSES FOR THE SYNTHESIS AND USES THEREOF
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
KR20230104176A (ko) 2020-11-02 2023-07-07 네오이뮨텍, 인코퍼레이티드 코로나바이러스의 치료를 위한 인터류킨-7의 용도
CA3195594A1 (en) 2020-11-05 2022-05-12 Byung Ha Lee Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
CA3201965A1 (en) 2020-12-14 2022-06-23 Kyle W.H. Chan Pde4 degraders, pharmaceutical compositions, and therapeutic applications
EP4284377A1 (en) 2021-01-27 2023-12-06 Shy Therapeutics LLC Methods for the treatment of fibrotic disease
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
US20220280585A1 (en) * 2021-03-05 2022-09-08 Poopermints, LLC Pharmaceutical composition containing champignon extract and peppermint and methods of use thereof
WO2022192545A1 (en) 2021-03-10 2022-09-15 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
WO2022251533A1 (en) 2021-05-27 2022-12-01 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
WO2022256437A1 (en) 2021-06-02 2022-12-08 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
WO2022263357A1 (en) 2021-06-14 2022-12-22 Argenx Iip Bv Anti-il-9 antibodies and methods of use thereof
CA3222240A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022266249A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2023055045A1 (ko) 2021-09-29 2023-04-06 주식회사 엔바이오스 코일드 코일 융합 단백질
US12017997B2 (en) 2021-10-22 2024-06-25 Prosetta Biosciences, Inc. Host-targeted pan-respiratory antiviral small molecule therapeutics
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
CN119836296A (zh) 2021-12-30 2025-04-15 新免疫技术有限公司 用il-7蛋白和vegf拮抗剂的组合治疗肿瘤的方法
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
WO2023129576A2 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
CA3251592A1 (en) 2022-02-17 2025-07-09 Novelty Nobility Inc. ANTIBODY-DRUG CONJUGATE
US12168673B2 (en) 2022-03-02 2024-12-17 Mitopower, Inc. Prodrugs derived from nicotinic acid and ribose
WO2023192904A1 (en) 2022-03-30 2023-10-05 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
US12187699B2 (en) 2022-04-14 2025-01-07 Bristol-Myers Squibb Company GSPT1 compounds and methods of use of the novel compounds
EP4519439A1 (en) 2022-05-05 2025-03-12 BioMarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
JP2025516555A (ja) 2022-05-10 2025-05-30 バイオセリックス， インコーポレイテッド Ｃｄｋタンパク質分解因子、医薬組成物、及び治療応用
CN119947735A (zh) 2022-05-19 2025-05-06 莱尔免疫制药公司 靶向nr4a3的多核苷酸及其用途
KR20250099113A (ko) 2022-09-09 2025-07-01 이노보 테라퓨틱스 인코포레이티드 CK1α 및 DUAL CK1α/GSPT1 분해 화합물
WO2024073473A1 (en) 2022-09-30 2024-04-04 Boulder Bioscience Llc Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
EP4604988A1 (en) 2022-10-21 2025-08-27 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
EP4608839A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
WO2024092037A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridone compounds
EP4608834A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing pyridine compounds
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
EP4626865A1 (en) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
EP4680632A2 (en) 2023-03-17 2026-01-21 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
AU2024254039A1 (en) 2023-04-07 2025-10-02 Diagonal Therapeutics Inc. Hinge-modified bispecific antibodies
KR20250168499A (ko) 2023-04-07 2025-12-02 다이애고널 테라퓨틱스 인코포레이티드 액티빈 a 수용체 유사 유형 1(alk1)에 대한 이중 특이적 효현성 항체
EP4702143A2 (en) 2023-04-24 2026-03-04 BioMarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
US20240368596A1 (en) 2023-05-05 2024-11-07 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
WO2024233642A1 (en) 2023-05-09 2024-11-14 Progentos Therapeutics, Inc. Heterocyclic compounds and uses thereof
AU2024276812A1 (en) 2023-05-19 2025-11-06 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to il12 receptor
KR20260033048A (ko) 2023-07-03 2026-03-10 네오이뮨텍, 인코퍼레이티드 이종이합체 fc 분자 및 이의 용도
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
TW202530223A (zh) 2023-09-27 2025-08-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ抑制劑
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
WO2025090519A1 (en) 2023-10-23 2025-05-01 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025147691A1 (en) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation
WO2025255341A1 (en) 2024-06-05 2025-12-11 Protego Biopharma, Inc. Tetrahydrofuranyl ire1/xbp1s activators

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3473490A (en) * 1966-01-17 1969-10-21 Camillo Corvi Mora Producing chronoactive pharmaceutical granules
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
JPS57171428A (en) * 1981-04-13 1982-10-22 Sankyo Co Ltd Preparation of coated solid preparation
DK58983D0 (da) * 1983-02-11 1983-02-11 Leo Pharm Prod Ltd Farmaceutisk praeparat
US4503030A (en) * 1983-06-06 1985-03-05 Alza Corporation Device for delivering drug to certain pH environments
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
DE3572440D1 (en) * 1984-06-19 1989-09-28 Basf Ag Gastro-resistant cylindrical pancreatine-microtablets
EP0212745B1 (en) * 1985-08-16 1991-04-10 The Procter & Gamble Company Drug particles having constant release
JPS6261916A (ja) * 1985-09-12 1987-03-18 Fujisawa Pharmaceut Co Ltd 持続性製剤
US5238686A (en) * 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
AU591248B2 (en) * 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
SE460945B (sv) * 1987-01-15 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av furosemid
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
US4925676A (en) * 1989-02-02 1990-05-15 Warner-Lambert Company Extended release gemfibrozil composition
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings

Also Published As

Publication number Publication date
JP3194974B2 (ja) 2001-08-06
AU654277B2 (en) 1994-11-03
ATE144138T1 (de) 1996-11-15
ZA912792B (en) 1992-12-30
WO1991016042A1 (en) 1991-10-31
IT9020054A0 (it) 1990-04-17
CA2035155A1 (en) 1991-10-18
EP0524989A1 (en) 1993-02-03
DE69122751D1 (de) 1996-11-21
TW223022B (it) 1994-05-01
IE911271A1 (en) 1991-10-23
SG46584A1 (en) 1998-02-20
JPH05506217A (ja) 1993-09-16
DE69122751T2 (de) 1997-02-13
KR930700077A (ko) 1993-03-13
PT97370A (pt) 1992-01-31
NZ237823A (en) 1992-09-25
DK0524989T3 (da) 1996-11-18
GR3021847T3 (en) 1997-02-28
EP0524989B1 (en) 1996-10-16
PT97370B (pt) 1998-08-31
ES2093097T3 (es) 1996-12-16
CA2040471A1 (en) 1991-10-18
KR100196256B1 (ko) 1999-06-15
IT9020054A1 (it) 1991-10-17
EP0453001A1 (en) 1991-10-23
JPH04224517A (ja) 1992-08-13
US5900252A (en) 1999-05-04
AU7679891A (en) 1991-11-11
RU2111743C1 (ru) 1998-05-27

Similar Documents

Publication Publication Date Title
IT1246382B (it) Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
ATE106717T1 (de) Orale heilmittelform für dauerverabreichung.
CA2045472C (en) Drug delivery compositions
US5681584A (en) Controlled release drug delivery device
DK0673645T3 (da) Farmaceutisk præparat til afgivelse af lægemidler i colon
ATE235235T1 (de) Arzneistoffverabreichungssystem auf basis von flüssigkristall-strukturen
EA200300752A1 (ru) Фармацевтическая композиция, имеющая сниженную тенденцию кристаллизации лекарственного ингредиента
DK0661045T3 (da) Hydrogelpræparat med forsinket frigivelse
HUP9802339A2 (hu) Darifenacint tartalmazó gyógyászati készítmények
EA200200126A1 (ru) Гидродинамически сбалансированная пероральная система доставки лекарства
DK0754452T3 (da) Farmaceutisk præparat i form af en overtrukket kapsel, der frigives i den nedre del af fordøjelsessystemet
DE69427466D1 (de) Bisacodyl dosierungsform
DK1028707T3 (da) Oftalmiske præparater med forlænget frigivelse og indeholdende vandopløselige medikamenter
NO992186D0 (no) System med forsinket avlevering for syresensitive medikamenter
MC2288A1 (fr) Systeme d'administration de medicament au niveau du colon
CY1108863T1 (el) Φαρμακευτικο σκευασμα εκτεταμενης απελευθερωσης ανεξαρτητης απο το ρη
ES2159630T3 (es) Sistema de administracion por via oral de proteinas g-csf quimicamente modificadas.
BR0011345A (pt) Composições com sabor mascarado
JP2024533274A (ja) 大きな生理活性物質及び賦形剤を含む医薬組成物
TNSN98049A1 (fr) Composition pharmaceutique a residence gastrique.
CN105828812A (zh) 胃内滞留口服药物组合物
FR2387032A1 (fr) Composition pharmaceutique pour l'administration orale de pancreatine
KR100302314B1 (ko) 세파클로르의서방성매트릭스제형
KR950700063A (ko) 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970327